title: Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
authors.affiliation: From Harvard Medical School and the Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center - both in Boston.
authors.forename: Bruce
authors.initials: B
authors.lastname: Furie
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage*; D000465:Algorithms; D000925:Anticoagulants / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D010644:Phenprocoumon / Q000008:administration & dosage*; D064417:Vitamin K Epoxide Reductases / Q000235:genetics*; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases; D000074:Acenocoumarol; D010644:Phenprocoumon